89.64
2.64 (3.03%)
| Previous Close | 87.00 |
| Volume | 602,309 |
| Price / Book | 16.60 |
| 52 Weeks Range |
| Operating Margin (TTM) | -4,865.98% |
| Diluted EPS (TTM) | -3.45 |
| Quarterly Revenue Growth (YOY) | -17.40% |
| Total Debt/Equity (MRQ) | 269.12% |
| Current Ratio (MRQ) | 1.25 |
| Operating Cash Flow (TTM) | -152.60 M |
| Levered Free Cash Flow (TTM) | -87.22 M |
| Return on Assets (TTM) | -48.60% |
| Return on Equity (TTM) | -196.12% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Abivax SA | Mixed | Bullish |
AIStockmoo Score
| Value 35% | -4.2 |
| AI Insight info | NA |
| Relative Valuation info | NA |
| Financial Health info | -4.2 |
| Timing 35% | 0.3 |
| AI Technical info | NA |
| Technical Oscillators info | -0.5 |
| Technical Moving Averages info | 1.5 |
| Smart Money 30% | 0.0 |
| Analyst Consensus info | 0.0 |
| Insider Activity info | NA |
| Environment | ×1.21 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | -22.5% |
| Pillar Agreement | ×1.18 |
| Not in score | |
| Price Volatility info | 5.0 |
| Final Score | -1.96 |
Select this tab to load the latest available analysis.
|
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Institutions | 50.19% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Darwin Global Management, Ltd. | 30 Jun 2026 | 3,621,583 |
| Helikon Investments Ltd | 30 Jun 2026 | 2,787,131 |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |